Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells
- PMID: 9045694
- DOI: 10.1074/jbc.272.10.6641
Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells
Abstract
Amyloid beta-protein (Abeta) is the major component of neuritic (amyloid) plaques in Alzheimer's disease, and its deposition is an early and constant event in the complex pathogenetic cascade of the disease. Although many studies have focused on the biosynthetic processing of the beta-amyloid precursor protein and on the production and polymerization of Abeta, understanding the degradation and clearance of Abeta has received very little attention. By incubating the conditioned medium of metabolically labeled Abeta-secreting cells with media of various cultured cell lines, we observed a time-dependent decrease in the amount of Abeta in the mixed media. The factor principally responsible for this decrease was a secreted metalloprotease released by both neural and non-neural cells. Among the cells examined, the microglial cell line, BV-2, produced the most Abeta-degrading activity. The protease was completely blocked by the metalloprotease inhibitor, 1,10-phenanthroline, and partially inhibited by EDTA, whereas inhibitors of other protease classes produced little or no inhibition. Substrate analysis suggests that the enzyme was a non-matrix metalloprotease. The protease cleaved both Abeta1-40 and Abeta1-42 peptides secreted by beta-amyloid precursor protein-transfected cells but failed to degrade low molecular weight oligomers of Abeta that form in the culture medium. Lipopolysaccharide, a stimulator of macrophages/microglia, activated BV-2 cells to increase their Abeta-degrading metalloprotease activity. We conclude that secreted Abeta1-40 and Abeta1-42 peptides are constitutively degraded by a metalloprotease released by microglia and other neural cells, providing a potential mechanism for the clearance of Abeta in brain tissue.
Similar articles
-
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.J Biol Chem. 1998 Dec 4;273(49):32730-8. doi: 10.1074/jbc.273.49.32730. J Biol Chem. 1998. PMID: 9830016
-
Proteolytic degradation of Alzheimer's disease amyloid beta-peptide by a metalloproteinase from microglia cells.J Neurochem. 1998 Feb;70(2):721-6. doi: 10.1046/j.1471-4159.1998.70020721.x. J Neurochem. 1998. PMID: 9453567
-
Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex.J Biol Chem. 1996 Apr 5;271(14):8443-51. doi: 10.1074/jbc.271.14.8443. J Biol Chem. 1996. PMID: 8626544
-
The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells.J Biol Chem. 1996 Nov 29;271(48):30929-34. doi: 10.1074/jbc.271.48.30929. J Biol Chem. 1996. PMID: 8940079
-
Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis.Neurobiol Aging. 2015 Jan;36(1):42-52. doi: 10.1016/j.neurobiolaging.2014.07.024. Epub 2014 Jul 24. Neurobiol Aging. 2015. PMID: 25169677
Cited by
-
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4162-7. doi: 10.1073/pnas.0230450100. Epub 2003 Mar 12. Proc Natl Acad Sci U S A. 2003. PMID: 12634421 Free PMC article.
-
Inflammation and Alzheimer's disease.Neurobiol Aging. 2000 May-Jun;21(3):383-421. doi: 10.1016/s0197-4580(00)00124-x. Neurobiol Aging. 2000. PMID: 10858586 Free PMC article. Review.
-
Insulin-Degrading Enzyme: Paradoxes and Possibilities.Cells. 2021 Sep 16;10(9):2445. doi: 10.3390/cells10092445. Cells. 2021. PMID: 34572094 Free PMC article.
-
Novel Microglia-based Therapeutic Approaches to Neurodegenerative Disorders.Neurosci Bull. 2023 Mar;39(3):491-502. doi: 10.1007/s12264-022-01013-6. Epub 2023 Jan 3. Neurosci Bull. 2023. PMID: 36593381 Free PMC article. Review.
-
Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.CNS Neurol Disord Drug Targets. 2009 Apr;8(2):128-43. doi: 10.2174/187152709787847298. CNS Neurol Disord Drug Targets. 2009. PMID: 19355933 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources